» Articles » PMID: 2307846

Complement C5a Activation of Phospholipase D in Human Neutrophils. A Major Route to the Production of Phosphatidates and Diglycerides

Overview
Journal J Immunol
Date 1990 Mar 1
PMID 2307846
Citations 17
Authors
Affiliations
Soon will be listed here.
Abstract

The contribution of phospholipase D (PLD) to the production of phosphatidic acid (PA) and diglyceride (DG) by C5a-stimulated human neutrophils has been studied. Membrane-associated 1-O-alkyl-phosphatidylcholine (alkyl-PC) was double labeled with 3H and 32P by incubating neutrophils with [3H]alkyl-lysoPC and alkyl-[32P]lysoPC. Upon stimulation with recombinant C5a, these labeled neutrophils produce 1-O-alkyl-phosphatidic acid (alkyl-PA) and, in the presence of ethanol, 1-O-alkyl-phosphatidyl-ethanol (alkyl-PEt), containing both 3H and 32P. Formation of radiolabeled alkyl-PEt parallels that of radiolabeled alkyl-PA and requires both extracellular Ca2+ and cytochalasin B. Furthermore, the 3H/32P ratios of alkyl-PA and alkyl-PEt formed during stimulation are very similar to that of th substrate alkyl-PC. These results demonstrate that, in C5a-stimulated neutrophils, alkyl-PA and alkyl-PEt are formed from alkyl-PC almost exclusively by PLD-catalyzed hydrolysis and transphosphatidylation, respectively. Upon C5a stimulation, neutrophils labeled with 3H and 32P also produce 1-O-[3H]alkyl-diglyceride [( 3H]alkyl-DG) and [32P]orthophosphate [( 32P]PO4), but not [32P]phosphocholine. [3H]Alkyl-DG and [32P]PO4 are formed in parallel, although temporally lagging behind alkyl-PA. Propranolol, a PA phosphohydrolase (PPH) inhibitor, decreases the formation of both [3H]alkyl-DG and [32P]PO4, although increasing alkyl-PA accumulation. These data support the conclusion that alkyl-DG is formed from alkyl-PC by the combined activities of PLD and PPH and not by phospholipase C (PLC). Furthermore, by using [3H]acyl-PC-labeled neutrophils, it is demonstrated that, like alkyl-PC, 1-acyl-PC is also degraded sequentially by PLD and PPH to 1-acyl-DG. Propranolol does not inhibit phosphoinositide-specific PLC and yet it causes almost complete inhibition of the total DG mass accumulation in C5a-stimulated neutrophils. We conclude that, in cytochalasin B-treated neutrophils stimulated with C5a, PLD-catalyzed hydrolysis of PC determines the levels of both PA and DG with potentially important ramifications for neutrophil-mediated defense functions.

Citing Articles

The Complement Receptors C3aR and C5aR Are a New Class of Immune Checkpoint Receptor in Cancer Immunotherapy.

Wang Y, Zhang H, He Y Front Immunol. 2019; 10:1574.

PMID: 31379815 PMC: 6658873. DOI: 10.3389/fimmu.2019.01574.


Complementing the inflammasome.

Triantafilou M, Hughes T, Morgan B, Triantafilou K Immunology. 2015; 147(2):152-64.

PMID: 26572245 PMC: 4717242. DOI: 10.1111/imm.12556.


Complement System Part I - Molecular Mechanisms of Activation and Regulation.

Merle N, Church S, Fremeaux-Bacchi V, Roumenina L Front Immunol. 2015; 6:262.

PMID: 26082779 PMC: 4451739. DOI: 10.3389/fimmu.2015.00262.


Complement System Part II: Role in Immunity.

Merle N, Noe R, Halbwachs-Mecarelli L, Fremeaux-Bacchi V, Roumenina L Front Immunol. 2015; 6:257.

PMID: 26074922 PMC: 4443744. DOI: 10.3389/fimmu.2015.00257.


Complement inhibition in cancer therapy.

Pio R, Ajona D, Lambris J Semin Immunol. 2013; 25(1):54-64.

PMID: 23706991 PMC: 3733085. DOI: 10.1016/j.smim.2013.04.001.